Psyence Biomedical Ltd. advances NPX-5 dosing in Australia. Discover how this trial strategy could shape global psychedelic drug development.
Discover how Plus Therapeutics Inc. is scaling REYOBIQ manufacturing for pivotal trials and what it means for radiopharmaceutical innovation.
Find out how Annamycin could bridge chemotherapy and immunotherapy in pancreatic cancer and what AACR 2026 data signals for future trials.
Bausch + Lomb’s PreserVision AREDS3 adds B vitamins to the AMD nutrition debate. Read what this could change for eye health and market strategy.
CatalYm has dosed the first patient in its visugromab Phase 2/3 cachexia trial. Read why this oncology move could matter far beyond weight gain.
Explore how TG Therapeutics, Inc.’s BRIUMVI data at AAN 2026 could reshape real-world MS treatment and adoption trends. Read the full analysis now.
CervoMed Inc. reveals neflamapimod MRI data in DLB. Discover how biomarker-driven trials could reshape neurodegeneration drug development.
Neurona Therapeutics’ rezanecel shows durable seizure reduction in epilepsy. Discover what this means for cell therapy innovation and future treatment pathways.
Find out how Tempest Therapeutics, Inc.’s CAR-T strategy could shape the next phase of cell therapy competition and multiple myeloma innovation.
Star Therapeutics won dual FDA designations for VGA039 in von Willebrand disease. Read what it could change, and what still needs proving.